Krónikus vesebetegség: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• AKT 0
• STAT3 1
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• STING 0
• MAPK 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• IL-1 1
• JAK 0
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

4752 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 500 000 EUR· until 2032. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finnország· EU contribution 4 273 568 EUR· until 2031. jan.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 2 693 628 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, Franciaország· EU contribution 1 498 100 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 325 435 EUR· until 2029. febr.

5 of 52 running projects, newest first. Listed amounts together: 145,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Frissítve: 2026. nov. 12.

  “Recruitment temporarily paused.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

  NCT04523727· Keryx Biopharmaceuticals· Frissítve: 2026. nov. 10.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CommunityRx-Kidney Health

  NCT07237295· University of North Carolina, Chapel Hill· Frissítve: 2026. nov. 5.

  “Unanticipated operational challenges. No safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Novo Nordisk A/S· Frissítve: 2026. nov. 4.

  “Interim futility analysis showed primary endpoint not achieved”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· Alexion Pharmaceuticals, Inc.· Frissítve: 2026. okt. 29.

  “The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CKD

  NCT05018845· The Foundation for Orthopaedics and Regenerative Medicine· Frissítve: 2026. okt. 20.

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

  NCT07786571· Sun Yat-sen University· Frissítve: 2026. okt. 16.

  “The study was withdrawn because the protocol was revised and would be replaced by an updated study design, prior to participant enrollment.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Solv Multi-Pass Hemodialysis System In-Center Clinical Study

  NCT07216885· Mozarc Medical US LLC· Frissítve: 2026. okt. 1.

  “Due to funding the study has been stopped. All subjects enrolled have completed the follow-up and have exited the study.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

  NCT06995144· Sarfez Pharmaceuticals, Inc.· Frissítve: 2026. szept. 28.

  “No participants enrolled”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

  NCT07223502· Sarfez Pharmaceuticals, Inc.· Frissítve: 2026. szept. 22.

  “No recruitment”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• The Effect of Intradialytic Exercise on Postural Abnormalities

  NCT07720401· Pardis Specialized Wellness Institute· Forrás

• Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5

  NCT06901960· Peking University First Hospital· Forrás

• A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

  NCT07024823· AstraZeneca· Forrás

• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Boehringer Ingelheim· Forrás

• A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

  NCT07931547· Novo Nordisk A/S· Forrás

• Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Forrás

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Boehringer Ingelheim· Forrás

• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Boehringer Ingelheim· Forrás

• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

  NCT07775846· Huijie Zhang· Forrás

• Transcutaneous Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease Autonomic Dysfunction

  NCT07927478· NYU Langone Health· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 22
• Cohort Studies 553
• Genome-Wide Association Study 79

• Impact of Clinical Pharmacist Integration on Weight Management and Transplant Eligibility Among Patients With End-Stage Kidney Disease With Obesity.

  J Am Coll Clin Pharm, 2026. dec.

• Model-Derived Iopamidol Clearance and Creatinine-Based Kidney Function Estimates After Trauma: A Retrospective Cohort Study.

  Pharmacotherapy, 2026. dec.

• Ratio of Red Blood Cell Distribution Width to Albumin Level and Mortality Outcomes in Population with Chronic Kidney Disease.

  Kidney Blood Press Res, 2026. okt.

• External validation and cross-center transportability of phenotypic age acceleration and laboratory frailty for postoperative mortality prediction: a dual-center cohort study.

  Front Endocrinol (Lausanne), 2026. okt.

• Prevalence of Fabry disease GLA variants among patients with parapelvic cysts: a Multicenter Italian Cohort Study.

  J Nephrol, 2026. okt.

• Pleural Aerobic Culture Status, Clinical Phenotypes, and In-Hospital Outcomes in Adult Pleural Infection: A Retro-Spective Cohort Study.

  Medicina (Kaunas), 2026. okt.

• Same-Day Discharge Versus Overnight Stay After Catheter Ablation: An Observational Matched-Cohort Study on Safety and Feasibility.

  Dtsch Arztebl Int, 2026. okt.

• Effect of uric acid and estimated glomerular filtration rate on the Fibrosis-4 index: A cross-sectional and cohort analysis.

  Medicine (Baltimore), 2026. okt.

• Predictors of Early Mortality After Open Aorto-Iliac Reconstruction in Patients with Aortoiliac Occlusive Disease: An Observational Cohort Study.

  Medicina (Kaunas), 2026. okt.

• Association of Neutrophil Percentage-to-Albumin Ratio (NPAR) With Pathological Features and Long-Term Prognosis in Diabetic Kidney Disease: A Cohort Study.

  FASEB J, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.